Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

Eevia Health Plc receives starting sales orders from new Asian customers

Eevia Health Plc, ("Eevia" or "The Company"), has received two small starting sales orders from South Korea and Taiwan, totaling approx. 24 KEUR for organically certified bilberry extracts.

The South Korean customer is new to Eevia. It is a natural health company based out of Soul selling its consumer products in Asia. The product is a highly concentrated and organically certified bilberry extract with 25% anthocyanins. The start order was for 13 KEUR.

Similarly, Eevia received a small order from a Taiwanese customer for 11 KEUR. This is also a bilberry extract, Eevia's branded Feno-Myrtillus 25 Organic (25% anthocyanins), which will be used as an ingredient in supplement formulas marketed in the Taiwanese domestic market.

Both orders were prepaid and shipped immediately upon payment.

"Although these are small start orders, which take less than a day to produce, we are happy to do business with Asian customers, which are keenly focused on high quality. We can do much more in Asia, and that may be one of our targets for 2023" says Anna-Maija Vanhatalo, Customer Service Manager, Eevia Health.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                         
Email: [email protected]                    
Telephone: +358 400 22 5967   

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

Eevia Health Plc is awarded a business development grant of 243 KEUR

Eevia Health Plc ("Eevia" or "The Company") has received a positive decision from Business Finland for a business development grant of 243 840 EUR. The grant is a 50% financing of a total project budget of 487.680 EUR. The project has two work packages.


Eevia Health Plc receives a 140 KSEK / 12 KEUR sales order for a Chaga extract product

Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for a Chaga extract from its US distributor Barrington Nutritionals.


Eevia Health Plc receives multiple smaller sales orders in total EUR 30k

Eevia Health ("Eevia" or "The Company") received several smaller sales orders for multiple products from multiple Finnish and European customers for a combined value of just over EUR 30k.


Eevia Health Plc receives a USD 200K sales order for Feno-Sambucus™ 7 Organic

Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.


FLAGGING OF A TRANSACTION BETWEEN PMDRS IN EEVIA HEALTH PLC

Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.


CORRECTION Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label. 

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.


Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.


Last day of trading in paid subscription shares (Swedish: BTA) in Eevia Health Plc

Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.


EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF CHANGE OF HOLDINGS BY CEO

Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.


EEVIA HEALTH PLC: FLAGGING NOTIFICATION OF NEW SHAREHOLDING

Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted